Under the agreement, GVK Bio will receive an initial payment and will be eligible for success-based milestone payments. GVK Bio will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies.
GVK Bio will utilize in-house capabilities in discovery chemistry, informatics, biology and ADME to advance this program.
Sanjay Reddy, managing director of GVK Bio, said: “This research agreement expands our work together and builds on GVK Bio’s core strengths. This agreement further validates India’s capability to do innovative research along with leading pharmaceutical and biotech companies.”